Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Filters
Results by year
Table representation of search results timeline featuring number of search results per year.
Year | Number of Results |
---|---|
2012 | 2 |
2018 | 1 |
2023 | 1 |
2024 | 1 |
Search Results
5 results
Results by year
Filters applied: . Clear all
Page 1
Effectiveness and Safety of Teriflunomide in Relapsing-Remitting Multiple Sclerosis and Improvements in Quality of Life: Results from the Real-World TERICARE Study.
Neurol Ther. 2023 Dec;12(6):2177-2193. doi: 10.1007/s40120-023-00557-7. Epub 2023 Oct 20.
Neurol Ther. 2023.
PMID: 37861931
Free PMC article.
Anatomical study with clinical significance of communicating and visceral branching of the cervical and upper thoracic sympathetic trunk.
Franco-Riveros VB, Pividori SM, Martin TI, Nicora FE, Lallana MC, Pontecorvo AA, Flores JC, Tubbs RS, Boezaart AP, Reina MA, Buchholz B.
Franco-Riveros VB, et al.
Clin Anat. 2024 Mar 12. doi: 10.1002/ca.24149. Online ahead of print.
Clin Anat. 2024.
PMID: 38469730
Item in Clipboard
Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension.
Kapoor R, Ho PR, Campbell N, Chang I, Deykin A, Forrestal F, Lucas N, Yu B, Arnold DL, Freedman MS, Goldman MD, Hartung HP, Havrdová EK, Jeffery D, Miller A, Sellebjerg F, Cadavid D, Mikol D, Steiner D; ASCEND investigators.
Kapoor R, et al.
Lancet Neurol. 2018 May;17(5):405-415. doi: 10.1016/S1474-4422(18)30069-3. Epub 2018 Mar 12.
Lancet Neurol. 2018.
PMID: 29545067
Clinical Trial.
Item in Clipboard
Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial.
Coles AJ, Twyman CL, Arnold DL, Cohen JA, Confavreux C, Fox EJ, Hartung HP, Havrdova E, Selmaj KW, Weiner HL, Miller T, Fisher E, Sandbrink R, Lake SL, Margolin DH, Oyuela P, Panzara MA, Compston DA; CARE-MS II investigators.
Coles AJ, et al.
Lancet. 2012 Nov 24;380(9856):1829-39. doi: 10.1016/S0140-6736(12)61768-1. Epub 2012 Nov 1.
Lancet. 2012.
PMID: 23122650
Clinical Trial.
Item in Clipboard
Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial.
Cohen JA, Coles AJ, Arnold DL, Confavreux C, Fox EJ, Hartung HP, Havrdova E, Selmaj KW, Weiner HL, Fisher E, Brinar VV, Giovannoni G, Stojanovic M, Ertik BI, Lake SL, Margolin DH, Panzara MA, Compston DA; CARE-MS I investigators.
Cohen JA, et al.
Lancet. 2012 Nov 24;380(9856):1819-28. doi: 10.1016/S0140-6736(12)61769-3. Epub 2012 Nov 1.
Lancet. 2012.
PMID: 23122652
Clinical Trial.
Item in Clipboard
Cite
Cite